Ronny Gal - The New York office of the U.S. Attorney's Office for the District of New York announced today that it filed a civil injunctive action and obtained an emergency court order to halt the litigation.  The SEC's complaint, filed in federal court in Manhattan, alleges that AbbVie Inc., a biopharmaceutical company based in New York City, and its CEO, Rob Mary, violated the antifraud provisions of the federal securities laws by failing to disclose that AbbVie was developing a biosimilar that was not approved in the U.S.  The SEC's complaint alleges that AbbVie violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, AbbVie has agreed to the entry of a final judgment that permanently enjoins it from violating the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. The settlement is subject to court approval.  The SEC's complaint charges AbbVie with violating Section 10(b) of the Exchange Act, Section 13(b) of the Exchange Act, and Rule 10b-5 thereunder. Without admitting or denying the SEC's allegations, AbbVie agreed to the entry of a final judgment permanently enjoining it from violating the antifraud provisions of Sections 10(b) and 13(b) of the Exchange Act. The settlement is subject to court approval. The SEC's investigation was conducted by Ronny Gal and supervised by Kelly L. Gibson. The litigation will be led by Mary Severino. The SEC appreciates the assistance of the U.S. Attorney's Office, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.